Procter & Gamble Health Limited Stock NSE India S.E.

Equities

PGHL

INE199A01012

Pharmaceuticals

End-of-day quote NSE India S.E. 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
4,729 INR +0.06% Intraday chart for Procter & Gamble Health Limited -0.12% -4.42%
Sales 2022 11.14B 134M Sales 2023 12.3B 148M Capitalization 87.13B 1.05B
Net income 2022 1.92B 23.11M Net income 2023 2.3B 27.55M EV / Sales 2022 5.95 x
Net cash position 2022 3.17B 38M Net cash position 2023 4.23B 50.79M EV / Sales 2023 6.74 x
P/E ratio 2022
36.1 x
P/E ratio 2023
38 x
Employees 1,407
Yield 2022
1.25%
Yield 2023
1.81%
Free-Float 47.83%
More Fundamentals * Assessed data
Dynamic Chart
Procter & Gamble Health Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Procter & Gamble Health Limited Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Procter & Gamble Hygiene to Discontinue Injection Production at Goa, Unit, India MT
Procter & Gamble Health Limited Discontinues Production of Injections at its Manufacturing Plant in Goa Effective September 30, 2023 CI
Procter & Gamble Health Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Procter & Gamble Health Limited Reports Earnings Results for the Fourth Quarter Ended June 30, 2023 CI
Procter & Gamble Health Limited Announces Change in Senior Management Personnel CI
Procter & Gamble India to invest $244 million to set up manufacturing facility RE
Procter & Gamble Health Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Procter & Gamble Health Appoints CFO MT
Procter & Gamble Health Limited Appoints Lokesh Chandak as Chief Financial Officer, Effective April 1, 2023 CI
Procter & Gamble Health's CFO Resigns MT
Procter & Gamble Health Limited Announces Board Changes CI
Procter & Gamble Health Limited Announces Resignation of Amit Gupta as Executive Director, Effective March 31, 2023 CI
Procter & Gamble Health Limited Announces Resignation of Amit Gupta as Chief Financial Officer, Effective March 31, 2023 CI
More news
1 day+0.06%
1 week-0.12%
Current month+0.41%
1 month-3.13%
3 months-9.63%
6 months-5.57%
Current year-4.42%
More quotes
1 week
4 642.55
Extreme 4642.55
4 825.00
1 month
4 642.55
Extreme 4642.55
4 850.00
Current year
4 642.55
Extreme 4642.55
5 642.85
1 year
4 575.00
Extreme 4575
5 642.85
3 years
3 870.10
Extreme 3870.1
6 576.00
5 years
2 891.45
Extreme 2891.45
7 500.00
10 years
611.05
Extreme 611.05
7 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 18-03-31
Director of Finance/CFO - 23-03-31
Compliance Officer - 21-06-30
Members of the board TitleAgeSince
Chairman 86 84-01-16
Director/Board Member 66 21-11-14
Director/Board Member 75 15-02-04
More insiders
Date Price Change Volume
24-04-23 4,729 +0.06% 3 971
24-04-23 4,726 +0.54% 7,406
24-04-22 4,701 +0.14% 6,568
24-04-19 4,695 -0.12% 8,445
24-04-18 4,700 -0.72% 9,099

End-of-day quote NSE India S.E., April 23, 2024

More quotes
Procter & Gamble Health Limited is an India-based company that is primarily engaged in the manufacturing of pharmaceutical products. The Company is engaged in the manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company’s brands include Cosome, Evion, Neurobion, Seven Seas, Nasivion, Polybion, and Livogen. Cosome is a medicine which is used to help relieve dry coughs and related congestion symptoms. Evion is a Vitamin E capsules. The Evion range has different variants with different levels of Vitamin E, such as Evion 400, Evion 200, and Evion 600. Neurobion offers a range of neurotropic B-Vitamins which are a combination to help treat nerve damage and regenerate the nerves to relieve symptoms. Nasivion Classic Nasal Spray starts working on a blocked nose in 25 seconds. Polybion is a brand that helps with release and hence supports an active life.
More about the company

Annual profits - Rate of surprise